Although pTau and Aβ are the most commonly used blood biomarkers for assessing amyloid pathologies and tauopathies in Alzheimer’s disease, recent studies have identified GFAP as a reliable alternative and potentially more sensitive indicator of pathological states. This evidence concerns the gene GFAP and amyloidosis.